Vera Therapeutics is a clinical stage biotech company that develops treatments for patients with immunological diseases in the United States. They are currently working on their lead candidate, atacicept, which is in a Phase IIb clinical trial for patients with immunoglobulin A nephropathy. The company is also developing another treatment, MAU868, for the treatment of BK viremia infections, which is currently in a Phase 2 clinical trial.